Binimetinib
| CAS No. | 606143-89-9 |
|---|---|
| MDL No. | MFCD22124525 |
| MF | C17H15BrF2N4O3 |
| MW | 441.20 |
| InChI Key | ACWZRVQXLIRSDF-UHFFFAOYSA-N |
Pricing & Availability
| Pack Size | Purity | Price | Availability | Action |
|---|---|---|---|---|
| - | - | On Request | On Request | |
| Custom synthesis and bulk supply options are available upon request. | ||||
Product Information
Binimetinib is a 1-methyl-1H-benzimidazole substituted at positions 4, 5, and 6 with fluorine, (4-bromo-2-fluorophenyl)nitrilo, and N-(2-hydroxyethoxy)aminocarbonyl groups, respectively. It is a MEK1/MEK2 inhibitor (IC50 = 12 nM) and is approved by the FDA for the treatment of unresectable or metastatic melanoma with BRAF V600E or V600K mutations, in combination with encorafenib. It functions as an MEK inhibitor, an antineoplastic agent, and an apoptosis inducer. It belongs to the classes of benzimidazoles, bromobenzenes, monofluorobenzenes, hydroxamic acid esters, and secondary amino compounds.
| CAS No. | 606143-89-9 |
|---|---|
| Product Name | Binimetinib |
Biological Targets
MAP2K1·MAP2K2
Associated Conditions
liver disease·melanoma·non-small cell lung carcinoma·Uveal Melanoma·metastatic melanoma·
* The information provided here is compiled from public sources and is for reference only.
